{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:16:19Z","timestamp":1785860179509,"version":"3.56.0"},"reference-count":71,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institutes of Health","award":["HL143892"],"award-info":[{"award-number":["HL143892"]}]},{"name":"National Institutes of Health","award":["HL147841"],"award-info":[{"award-number":["HL147841"]}]},{"name":"National Institutes of Health","award":["HL134608"],"award-info":[{"award-number":["HL134608"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCDD"],"abstract":"<jats:p>Cardiovascular diseases (CVDs) represent a significant global health burden, demanding innovative therapeutic approaches. In recent years, mRNA therapeutics have emerged as a promising strategy to combat CVDs effectively. Unlike conventional small-molecule drugs, mRNA therapeutics enable the direct modulation of cellular functions by delivering specific mRNA molecules to target cells. This approach offers unprecedented advantages, including the ability to harness endogenous cellular machinery for protein synthesis, thus allowing precise control over gene expression without insertion into the genome. This review summarizes the current status of the potential of cell-specific mRNA therapeutics in the context of cardiovascular diseases. First, it outlines the challenges associated with traditional CVD treatments and emphasizes the need for targeted therapies. Subsequently, it elucidates the underlying principles of mRNA therapeutics and the development of advanced delivery systems to ensure cell-specificity and enhanced efficacy. Notably, innovative delivery methods such as lipid nanoparticles and exosomes have shown promise in improving the targeted delivery of mRNA to cardiac cells, activated fibroblasts, and other relevant cell types. Furthermore, the review highlights the diverse applications of cell-specific mRNA therapeutics in addressing various aspects of cardiovascular diseases, including atherosclerosis, myocardial infarction, heart failure, and arrhythmias. By modulating key regulatory genes involved in cardiomyocyte proliferation, inflammation, angiogenesis, tissue repair, and cell survival, mRNA therapeutics hold the potential to intervene at multiple stages of CVD pathogenesis. Despite its immense potential, this abstract acknowledges the challenges in translating cell-specific mRNA therapeutics from preclinical studies to clinical applications like off-target effects and delivery. In conclusion, cell-specific mRNA therapeutics have emerged as a revolutionary gene therapy approach for CVD, offering targeted interventions with the potential to significantly improve patient outcomes.<\/jats:p>","DOI":"10.3390\/jcdd11020038","type":"journal-article","created":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T04:05:46Z","timestamp":1706241946000},"page":"38","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cell-Specific mRNA Therapeutics for Cardiovascular Diseases and Regeneration"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8168-3004","authenticated-orcid":false,"given":"Raj","family":"Kishore","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Sciences, Temple University, Philadelphia, PA 19140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit","family":"Magadum","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences, Temple University, Philadelphia, PA 19140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart Disease and Stroke Statistics\u20142023 Update: A Report from the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nature10147","article-title":"Heart regeneration","volume":"473","author":"Laflamme","year":"2011","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1126\/science.1200708","article-title":"Transient Regenerative Potential of the Neonatal Mouse Heart","volume":"331","author":"Porrello","year":"2011","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1161\/CIRCULATIONAHA.119.044619","article-title":"Apical resection prolongs the cell cycle activity and promotes myocardial regeneration after left ventricular injury in neonatal pig","volume":"142","author":"Zhao","year":"2020","journal-title":"Circulation"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1161\/CIRCULATIONAHA.118.034886","article-title":"Regenerative Potential of Neonatal Porcine Hearts","volume":"138","author":"Zhu","year":"2018","journal-title":"Circulation"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.4161\/cc.4.10.2081","article-title":"Cardiomyocyte proliferation: A platform for mammalian cardiac repair","volume":"4","author":"Engel","year":"2005","journal-title":"Cell Cycle"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature22978","article-title":"The extracellular matrix protein agrin promotes heart regeneration in mice","volume":"547","author":"Bassat","year":"2017","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/nm1619","article-title":"Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair","volume":"13","author":"Hajjar","year":"2007","journal-title":"Nat. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nature15372","article-title":"Epicardial FSTL1 reconstitution regenerates the adult mammalian heart","volume":"525","author":"Wei","year":"2015","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nature11739","article-title":"Functional screening identifies miRNAs inducing cardiac regeneration","volume":"492","author":"Eulalio","year":"2012","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1161\/CIRCULATIONAHA.119.043067","article-title":"Pkm2 Regulates Cardiomyocyte Cell Cycle and Promotes Cardiac Regeneration","volume":"141","author":"Magadum","year":"2020","journal-title":"Circulation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1126\/science.1199010","article-title":"Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size","volume":"332","author":"Heallen","year":"2011","journal-title":"Science"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.cell.2018.02.014","article-title":"Regulation of Cell Cycle to Stimulate Adult Cardiomyocyte Proliferation and Cardiac Regeneration","volume":"173","author":"Mohamed","year":"2018","journal-title":"Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature12054","article-title":"Meis1 regulates postnatal cardiomyocyte cell cycle arrest","volume":"497","author":"Mahmoud","year":"2013","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00129784-200505060-00002","article-title":"ACE inhibitors in heart failure: What more do we need to know?","volume":"5","author":"Demers","year":"2005","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e000119","DOI":"10.1161\/JAHA.113.000119","article-title":"Gene therapy to treat cardiovascular disease","volume":"2","author":"Wolfram","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1161\/CIRCRESAHA.117.311311","article-title":"RNA Therapeutics in Cardiovascular Disease","volume":"123","author":"Lucas","year":"2018","journal-title":"Circ. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1161\/CIRCRESAHA.119.315856","article-title":"Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease","volume":"126","author":"Huang","year":"2020","journal-title":"Circ. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41467-018-04252-2","article-title":"The CRISPR tool kit for genome editing and beyond","volume":"9","author":"Adli","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Zhang, M., Bahal, R., Rasmussen, T., Manautou, J., and Zhong, X. (2021). The growth of siRNA-based therapeutics: Updated clinical studies. Biochem. Pharmacol., 189.","DOI":"10.1016\/j.bcp.2021.114432"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Muramatsu","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.cjca.2011.02.005","article-title":"Targeted gene therapy for the treatment of heart failure","volume":"27","author":"Rapti","year":"2011","journal-title":"Can. J. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/jcp.21173","article-title":"Gene therapy: The first two decades and the current state-of-the-art","volume":"213","author":"Flotte","year":"2007","journal-title":"J. Cell Physiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/hrt.2007.116483","article-title":"Gene therapy: Targeting the myocardium","volume":"94","author":"Lyon","year":"2008","journal-title":"Heart"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1152\/physrev.00039.2007","article-title":"Designing heart performance by gene transfer","volume":"88","author":"Davis","year":"2008","journal-title":"Physiol. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/mt.2008.76","article-title":"Analysis of AAV serotypes 1\u20139 mediated gene expression and tropism in mice after systemic injection","volume":"16","author":"Zincarelli","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.ymthe.2018.04.024","article-title":"Exosomes in Myocardial Repair: Advances and Challenges in the Development of Next-Generation Therapeutics","volume":"26","author":"Adamiak","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1161\/CIRCULATIONAHA.122.063759","article-title":"Extracellular Vesicle\u2013Encapsulated Adeno-Associated Viruses for Therapeutic Gene Delivery to the Heart","volume":"148","author":"Li","year":"2023","journal-title":"Circulation"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.ymthe.2023.01.021","article-title":"Extracellular vesicles: The next generation in gene therapy delivery","volume":"31","author":"Cecchin","year":"2023","journal-title":"Mol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41563-023-01472-w","article-title":"Hydrogels for RNA delivery","volume":"22","author":"Zhong","year":"2023","journal-title":"Nat. Mater."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Buckstein","year":"2005","journal-title":"Immunity"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.omtn.2018.08.021","article-title":"Ablation of a Single N-Glycosylation Site in Human FSTL 1 Induces Cardiomyocyte Proliferation and Cardiac Regeneration","volume":"13","author":"Magadum","year":"2018","journal-title":"Mol. Ther.-Nucleic Acids"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1161\/CIRCULATIONAHA.120.047211","article-title":"Specific Modified mRNA Translation System","volume":"142","author":"Magadum","year":"2020","journal-title":"Circulation"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ymthe.2018.11.018","article-title":"mRNA-Based Protein Replacement Therapy for the Heart","volume":"27","author":"Magadum","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2004661","DOI":"10.1002\/advs.202004661","article-title":"Therapeutic Delivery of Pip4k2c-Modified mRNA Attenuates Cardiac Hypertrophy and Fibrosis in the Failing Heart","volume":"8","author":"Magadum","year":"2021","journal-title":"Adv. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ymthe.2017.03.016","article-title":"Optimizing Cardiac Delivery of Modified mRNA","volume":"25","author":"Sultana","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.omtm.2020.03.019","article-title":"Optimization of 5\u2032 Untranslated Region of Modified mRNA for Use in Cardiac or Hepatic Ischemic Injury","volume":"17","author":"Sultana","year":"2020","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/nbt.2682","article-title":"Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction","volume":"31","author":"Zangi","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Magadum, A. (2022). Modified mRNA Therapeutics for Heart Diseases. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232415514"},{"key":"ref_41","first-page":"91","article-title":"Activation of complement by hemodialysis membrane","volume":"31","author":"Kojima","year":"1989","journal-title":"Nihon Jinzo Gakkai shi"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging Issues in AAV-Mediated In Vivo Gene Therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: Overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.devcel.2008.12.007","article-title":"Cardiac fibroblasts regulate myocardial proliferation through beta1 integrin signaling","volume":"16","author":"Ieda","year":"2009","journal-title":"Dev. Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.str.2004.03.015","article-title":"Structure of protein L7Ae bound to a K-turn derived from an archaeal box H\/ACA sRNA at 1.8 \u00c5 resolution","volume":"12","author":"Hamma","year":"2004","journal-title":"Structure"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nbt.3301","article-title":"Mammalian synthetic circuits with RNA binding proteins for RNA-only delivery","volume":"33","author":"Wroblewska","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrd3864","article-title":"MicroRNA therapeutics for cardiovascular disease: Opportunities and obstacles","volume":"11","author":"Olson","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1261\/rna.2414110","article-title":"MicroRNA sponges: Progress and possibilities","volume":"16","author":"Ebert","year":"2010","journal-title":"RNA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nm1569","article-title":"The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2","volume":"13","author":"Yang","year":"2007","journal-title":"Nat. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/cvr\/cvaa324","article-title":"Cardiac fibrosis","volume":"117","author":"Frangogiannis","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.yjmcc.2015.08.016","article-title":"Fibroblast activation protein alpha expression identifies activated fibroblasts after myocardial infarction","volume":"87","author":"Tillmanns","year":"2015","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1161\/CIRCRESAHA.116.308643","article-title":"Targeted Ablation of Periostin-Expressing Activated Fibroblasts Prevents Adverse Cardiac Remodeling in Mice","volume":"118","author":"Kaur","year":"2016","journal-title":"Circ. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","article-title":"Targeting cardiac fibrosis with engineered T cells","volume":"573","author":"Aghajanian","year":"2019","journal-title":"Nature"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4103\/1735-5362.235156","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: Applications, advantages and disadvantages","volume":"13","author":"Ghasemiyeh","year":"2018","journal-title":"Res. Pharm. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nrm.2017.138","article-title":"Understanding the diversity of membrane lipid composition","volume":"19","author":"Harayama","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_58","first-page":"1053","article-title":"Efficient hepatic delivery and protein expression enabled by optimized mRNA and ionizable lipid nanoparticle","volume":"5","author":"Yang","year":"2020","journal-title":"Bioact. Mater."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1073\/pnas.86.16.6077","article-title":"Cationic liposome-mediated RNA transfection","volume":"86","author":"Malone","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"6867","DOI":"10.1016\/j.biomaterials.2010.05.027","article-title":"The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation","volume":"31","author":"Kedmi","year":"2010","journal-title":"Biomaterials"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1194\/jlr.R800058-JLR200","article-title":"Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall","volume":"50","author":"Getz","year":"2009","journal-title":"J. Lipid Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41565-017-0043-5","article-title":"A modular platform for targeted RNAi therapeutics","volume":"13","author":"Kedmi","year":"2018","journal-title":"Nat. Nanotechnol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1126\/science.aay3638","article-title":"A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis","volume":"371","author":"Krienke","year":"2021","journal-title":"Science"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1021\/acs.biomac.7b01356","article-title":"Systemic mRNA Delivery to the Lungs by Functional Polyester-based Carriers","volume":"18","author":"Yan","year":"2017","journal-title":"Biomacromolecules"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"24560","DOI":"10.18632\/oncotarget.4183","article-title":"RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients","volume":"6","author":"Golan","year":"2015","journal-title":"Oncotarget"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41569-020-00499-9","article-title":"Targeted delivery of therapeutic agents to the heart","volume":"18","author":"Sahoo","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41586-023-06800-3","article-title":"N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting","volume":"625","author":"Mulroney","year":"2024","journal-title":"Nature"}],"container-title":["Journal of Cardiovascular Development and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3425\/11\/2\/38\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:49:44Z","timestamp":1760104184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3425\/11\/2\/38"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,26]]},"references-count":71,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["jcdd11020038"],"URL":"https:\/\/doi.org\/10.3390\/jcdd11020038","relation":{},"ISSN":["2308-3425"],"issn-type":[{"value":"2308-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,26]]}}}